REINACH, Switzerland, April 15 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that it will host a conference call on Thursday 17 April 2008 at 8.30am CET. In this conference call, a leading expert will discuss the medical need and developments in the area of anti-infective drugs as well as the outcome of a recent meeting of the Anti-Infective Drugs Advisory Committee. During that meeting, the committee discussed product development and clinical trial design for both mild/moderate and moderate/severe community acquired pneumonia (CAP). A primary objective for the committee deliberations was to discuss issues relating to clinical trial design.
During the conference call, Arpida will also discuss the clinical data from the ASSIST-1 and ASSIST-2 trials with intravenous iclaprim in complicated Skin and Skin Structure Infections (cSSSI). In addition, the pooled analysis of the clinical data from these two pivotal Phase III trials will be discussed. Part of the data has already been published in earlier press releases, some additional statistical data, not previously published, will also be discussed. All data, as well as the dial-in details, will be made available via a press release on 17 April, prior to the conference call.
About Arpida Ltd.
Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.
Arpida's leading product candidate is intravenous iclaprim, a potent
antibacterial that targets severe infections requiring hospital treatment,
including those caused by methicillin-resistant Staphylococcus aureus
(MRSA). The clinical programme for the first indication, complicated skin
and skin structure infections (cSSSI), has been co
|SOURCE Arpida Ltd.|
Copyright©2008 PR Newswire.
All rights reserved